SMAD2, has been shown to have tumor-suppressive functions in endometrial carcinoma cells, and the inhibition of its activity has been associated with the constituent activation of the PI3K/AKT pathway, increased proliferation and decreased apoptosis (71). This evidence concerns the gene SMAD2 and endometrial carcinoma.